n°241

October 2022

Issue Contents
Editorial

Free  An African covid-19 vaccine, despite foot-dragging by drug companies

p.227

Marketing Authorisations


Estetrol + drospirenone (Drovelis°) for oral contraception

p.229-231
An insufficiently evaluated oestrogen combined with an unnecessarily dangerous progestogen

Editors' opinion. The rules for evaluating oral hormonal contraceptives must change!

p.231

Sacituzumab govitecan (Trodelvy°) in certain triple-negative breast cancers after multiple treatment failures

p.232-233
Extension of survival, but with frequent gastrointestinal and haematological adverse effects

Sodium oxybate (Xyrem°) in narcolepsy with cataplexy, from 7 years of age

p.234-235

Tixagevimab + cilgavimab (Evusheld°) in the prevention of covid-19

p.235

Queries and Comments. How protective is tixagevimab + cilgavimab (Evusheld°) against the Sars-CoV-2 Omicron variant?

p.236-237

Daratumumab + lenalidomide + dexamethasone as first-line treatment for certain multiple myelomas

p.238

Free  Trastuzumab deruxtecan (Enhertu°) in HER2-positive metastatic breast cancer

p.239

Editors' opinion. The magic of words

p.239

Subcutaneous daratumumab (Darzalex°) in certain multiple myelomas

p.240

Enzalutamide (Xtandi°) in metastatic hormone-sensitive prostate cancer

p.240

Adverse Effects


Viral vector covid-19 vaccines authorised in the European Union: a review of their adverse effects

p.241-243

Drug-induced skin ulcers

p.244-245

Oral administration of an injectable form: a little-studied practice with known risks

p.245

Inset. Questions to consider when using an injectable form orally

p.245

Oral anticoagulants: arthralgia without bleeding

p.246

Sirolimus, everolimus: ovarian cysts

p.246

Latanoprost and other "prosts" as eye drops: pregnancy loss

p.247

Common stem: -tecan

p.247

Outlook


Ellen 't Hoen: The public interest should be more central to government policy

p.248-249

Conflicts of interest in medical faculties and hospitals (continued)

p.250

Free  Antibiotic resistance: a growing threat

p.251

Masthead


Free  Masthead

p.226

The complete contents of 
this issue of Prescrire International
are available for download by
Prescrire International subscribers.
Certain texts are also available to
non-subscribers for free download,
as indicated. 

 

Subscribe